Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635718 | PMC |
| http://dx.doi.org/10.5853/jos.2015.17.3.366 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis.
Rev Cardiovasc Med
January 2025
Department of Cardiology, Affiliated Hospital of Guilin Medical University, 541001 Guilin, Guangxi, China.
Background: To compare the efficacy and safety of novel oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in nonvalvular atrial fibrillation (NVAF) patients with left atrial/left atrial thrombosis through a systematic review and meta-analysis.
Methods: The CBM (China Biology Medicine disc), CNKI (China National Knowledge Infrastructure), VIP (Chinese Technology Periodical Database), Wanfang, PubMed, Embase, Cochrane Library, and Web of Science databases were searched for relevant studies from their inception to June 30, 2022.
Results: Twelve articles (eight cohort studies and four randomized controlled trials) involving 982 patients were included.
Clinical effectiveness and safety comparison between direct oral anticoagulants and warfarin for nonvalvular atrial fibrillation patients following percutaneous left atrial appendage closure operation intervention: a prospective observational study.
BMC Pharmacol Toxicol
January 2025
Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
The main objective of this study was to investigate the optimal post-left atrial appendage closure (LAAC) anticoagulation strategy, focusing on minimizing device-related thrombosis (DRT) and thromboembolism (TE) events without increasing bleeding risk. After successful LAAC, consecutive participants were treated with 45-day anticoagulants (rivaroxaban 15 mg daily, dabigatran 110 mg twice a day, and warfarin). The efficacy endpoints included DRT, TE, and hospital readmissions due to cardiac caused, while safety endpoints encompassed bleeding events, monitored over a 12-month follow-up period.
View Article and Find Full Text PDFIntroduction Parenteral heparin is widely used as bridging therapy while optimising oral anticoagulation(OAC). Newer Direct-Acting OACs(DOACs) attain therapeutic effect very quickly. We report the use of dabigatran as bridging therapy during warfarin optimization for cardioembolic stroke in two patients who opted to receive warfarin for long-term anticoagulation for secondary stroke prevention.
View Article and Find Full Text PDFDabigatran-induced Enterococcus Necrotizing Fasciitis in Medically Unfit Patient with Successful Conservative Treatment Outcome: A Case Report.
Malays Orthop J
November 2024
Department of Orthopaedic Surgery, Miri Hospital, Miri, Malaysia.
A 54-year-old gentleman with underlying hypertension and congestive cardiac disease was diagnosed with left lower limb necrotizing fasciitis following commencement of oral dabigatran. Small bruises on the limb progressed to full-blown sepsis. The calculated perioperative risk for surgery was unfavourable.
View Article and Find Full Text PDFEsophageal Damage Following Left Atrial Ablation in a Patient on Dabigatran: Adding Insult to Injury.
Eur J Case Rep Intern Med
September 2024
Department of Gastroenterology, Faculty of Medicine, University of Balamand, El Koura, Lebanon.
Unlabelled: Dabigatran, a commonly prescribed anticoagulant medication, has been associated with esophagitis, referred to as dabigatran-induced esophagitis (DIE). We report a case of DIE occurring in a patient following left atrial ablation for atrial fibrillation. This case emphasizes the importance of recognizing the possible combined detrimental effects of left atrial ablation and dabigatran on the esophageal mucosa and highlights the clinical and endoscopic characteristics associated with DIE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!